Feb 01–04, 2026 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers:
Paul Carter, John R. Desjarlais, and E. Sally Ward

-
Scientific Organizers: Paul Carter, John R. Desjarlais, and E. Sally Ward
Paul Carter, PhD
Genentech, Inc.
John R. Desjarlais, PhD
Xencor, Inc.
E. Sally Ward, PhD
University of Southampton
***Meeting program subject to change.
Available Formats: = In Person = On DemandSunday, February 1, 2026
Fundraising
Booking Function
Merchandise Options
Registration Options
Monday, February 2, 2026
Lessons Learned from 30 Years of ADC Development
How Far are we from Designing an Antibody Therapeutic on a Computer
Unsupervised Evolution of Protein and Antibody Complexes with a Structure-Informed Language Model
Combining Active Learning with a Rapid Synthetic Biology Platform to Design Therapeutic Antibodies
Antibody Activation using Ca2+ or ATP-Switches
Talk Title to be Announced
Engineering of Hypoimmunogenic Biotherapeutics through a Novel bioconjugate Platform
Tuesday, February 3, 2026
AI/ML for Biologics Drug Discovery for Immunology
Degraders to Attack the Cancer Surfaceomewell
Engineering Antibodies to Improve High Concentration Properties for Subcutaneous Delivery
Targeting Subcellular Trafficking for the Generation of Therapeutics
Remote Presentation: Computational Design of Proteins for Therapeutic Applications
Optimizing ADC Delivery by Avidity/Affinity Tuning
Antibody-Oligonucleotide Conjugates
Wednesday, February 4, 2026
CD28 Bispecifics for Costimulation of T Cells
Proximity Labeling to Identify Target Pairs for ADCs and T Cell Engagers
T Cell Engagers
Recruitment of Dendritic Cells with Bispecifics / Fc Glycoengineering
Agonist MuSK Antibodies for the Treatment of Myasthenia Gravis
Human Monoclonal Antibodies for Emerging Infections
New Antibodies Against an Old Virus
Thursday, February 5, 2026
Subscribe for Updates